Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Journey Medical Corp (DERM) Insider Trading Activity

    Healthcare • Drug Manufacturers - Specialty & Generic • 41 employees

    Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

    Total Value

    -$367,846.02

    Total Shares

    -71,921

    Average Trade Value

    -$91,961.51

    Most Active Insider

    Maraoui Claude

    Total Activity: $360,762

    Largest Single Transaction

    $145,661

    by Maraoui Claude on Mar 4, 2025

    30-Day Activity

    2 Transactions

    Volume: 47,048 shares
    Value: $238,755

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    President CEO
    Director, Officer
    Mar 5, 2025 18,147 $93,094 2,092,874 (-0.9%) Sale
    President CEO
    Director, Officer
    Mar 4, 2025 28,901 $145,661 2,111,021 (-1.4%) Sale
    President CEO
    Director, Officer
    Mar 3, 2025 23,508 $122,007 2,139,922 (-1.1%) Sale
    CFO
    Officer
    Feb 21, 2025 1,365 $7,084 45,966 (-3.0%) Sale